Moderna flu mRNA vaccine tested in clinical trial
Moderna has started testing for mRNA flu Serum In clinical trials, with the company announcing Wednesday that early participants have been dosed in the Phase 1/2 study. The vaccine, mRNA-1010, is Moderna’s first seasonal influenza vaccine to enter clinical trials and will target influenza A H1n1, H3N2, and influenza B Yamagata and Victoria.
The company aims to enroll 180 participants aged 18 and over into the trial, and ultimately aims to study combination vaccines to target multiple respiratory viruses such as SARS-CoV-2 and RSV.
“We are pleased to begin this phase 1/2 study of mRNA-1010, the first mRNA candidate seasonal influenza vaccine to enter the clinic,” Stefan Bancel, CEO of Moderna He said in a press release. “Respiratory vaccines are an important pillar of our overall mRNA vaccine strategy. We believe the advantages of mRNA vaccines include the ability to combine different antigens to protect against multiple viruses and the ability to rapidly respond to respiratory viruses, such as influenza, SARS-CoV-2 and RSV.”
Traditionally, annual flu vaccines see efficacy of 40-60%, but new mRNA-based COVID-19 shots have seen rates above 90%. Moderna’s COVID-19, specifically, was observed to have an efficacy of 94.1% in those who received two doses.
“Our vision is to develop a combined mRNA vaccine so that people can get one injection every fall for highly effective protection against the most problematic respiratory viruses,” Bancel said. “We look forward to developing our primary method for preventive mRNA vaccines so that we can continue to make an impact on global public health.”